|drug2380||PEP flute Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
|D018352||Coronavirus Infections NIH||0.03|
There are 2 clinical trials
Electrocardiographic (ECG) evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The present study involves three different phases of evaluation of the ECG traces of hospitalized patients with SARS-CoV-2 infection. - Phase 1: it is proposed to collect and retrospectively analyze the ECGs of hospitalized patients with severe SARS-CoV-2 infection which led to invasive ventilation or patient death as a consequence and, if available, also possible troponin dosage; - Phase 2: aims to collect and analyze the ECGs of consecutive hospitalized patients with SARS-CoV-2 infection and evaluate their relationship with the course of the disease, cardiac involvement and prognosis; - Phase 3: it is proposed to repeat ECG and to carry out echocardiogram to patients with SARS-CoV-2 infection after 3 months from hospital discharge by simultaneously performing, if deemed clinically indicated, also cardiac magnetic resonance. In this phase, any evolutions of ECG alterations of the acute phase will be described and the relationship with cardiac involvement will be assessed.
Description: Describe the ECG characteristics in patients presenting with severe form of SARS-CoV-2 infectionMeasure: Phase 1: ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection Time: 1 month
Description: To evaluate the correlation between ECG signs and cardiac involvement in the acute phase • Assess the correlation between ECG signs and mortality in the acute phaseMeasure: Phase 2: Correlation between ECG signs and needs for invasive mechanical ventilation and/or mortality in the acute phase Time: 6 months
Description: To evaluate the correlation between acute phase ECG signs and chronic phase cardiac involvement • evaluate the appearance, in the short-term follow-up, of signs of cardiac involvement (cardiomyopathies and conduction disorders in particular)Measure: Phase 3: Correlation between ECG signs and cardiac involvement and mortality in the chronic phase Time: 12 months
The current COVID-19 pandemic (caused by the SARS-CoV-2 virus) represents the biggest medical challenge in decades. Whilst COVID-19 mainly affects the lungs it also affects multiple organ systems, including the cardiovascular system. There are documented associations between severity of disease and risk of death and To provide all the information required by review bodies and research information systems, we ask a number of specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and members of the public. Please read the guidance notes for advice on this section. 5 DRAFT Full Set of Project Data IRAS Version 5.13 advancing age, male sex and associated comorbid disease (hypertension, ischaemic heart disease, diabetes, obesity, COPD and cancer). The most common complications include cardiac dysrhythmia, cardiac injury, myocarditis, heart failure, pulmonary embolism and disseminated intravascular coagulation. It is thought that the mechanism of action of the virus involves binding to a host transmembrane enzyme (angiotensin- converting enzyme 2 (ACE2)) to enter some lung, heart and immune cells and cause further damage. While ACE2 is essential for viral invasion, it is unclear if the use of the common antihypertensive drugs ACE inhibitors or angiotensin receptor blockers (ARBs) alter prognosis. This study aims to look closely at the health of the vascular system of patients after being treated in hospital for COVID-19 (confirmed by PCR test) and compare them to patients who had a hospital admission for suspected COVID-19 (negative PCR test) . Information from this study is essential so that clinicians treating patients with high blood pressure understand the impact of the condition and these hypertension medicines in the context of the current COVID-19 pandemic. This will allow doctors to effectively treat and offer advice to patients currently prescribed these medications or who are newly diagnosed with hypertension.
Description: Ambulatory Blood Pressure Monitoring systolic blood pressureMeasure: ABPM systolic blood pressure Time: 24 hours (all day and night)
Description: Ambulatory Blood Pressure Monitoring diastolic blood pressureMeasure: 24-hr ABPM DBP Time: 24 hours (all day and night)
Description: Day Ambulatory Blood Pressure Monitoring systolic blood pressureMeasure: day ABPM SBP Time: 8am to 8pm
Description: Day Ambulatory Blood Pressure Monitoring diastolic blood pressureMeasure: day ABPM DBP Time: 8am to 8pm
Description: Night Ambulatory Blood Pressure Monitoring systolic blood pressureMeasure: night ABPM SBP Time: 8pm to 8am
Description: Night Ambulatory Blood Pressure Monitoring diastolic blood pressureMeasure: night ABPM DBP Time: 8pm to 8am
Description: The fall in pressure, called the "dip", is defined as the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day valueMeasure: dipping status Time: 24 hours (all day and night)
Description: he morning surge was defined as the difference between the mean systolic blood pressure during the 2 hours after waking and arising minus the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep.Measure: morning surge Time: 24 hours (all day and night)
Description: 24 hour Ambulatory Blood Pressure Monitoring heart rateMeasure: 24 hour ABPM HR Time: 24hr (all day and night)
Description: Day Ambulatory Blood Pressure Monitoring heart rateMeasure: day ABPM HR Time: 8 am to 8 pm
Description: Night Ambulatory Blood Pressure Monitoring heart rateMeasure: night ABPM HR Time: 8pm to 8 am
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports